BioCentury | Aug 31, 2018
Clinical News

Ultragenx's Mepsevii gets European approval

...yet set a European launch date. Mepsevii, an enzyme replacement therapy consisting of recombinant human glucuronidase beta...
BioCentury | Aug 27, 2018
Company News

Ultragenyx's Mepsevii gets European approval

...yet set a European launch date. Mepsevii, an enzyme replacement therapy consisting of recombinant human glucuronidase beta...
BioCentury | Apr 20, 2018
Clinical News

Ultragenyx gains rare disease approval, voucher

...with only 200 patients worldwide. Mepsevii is an enzyme replacement therapy consisting of recombinant human glucuronidase beta...
BioCentury | Apr 17, 2018
Company News

Ultragenyx gains rare disease approval, voucher

...with only 200 patients worldwide. Mepsevii is an enzyme replacement therapy consisting of recombinant human glucuronidase beta...
BioCentury | Dec 22, 2017
Company News

Novartis buys Priority Review voucher from Ultragenyx

...with about 200 patients worldwide. Mepsevii is an enzyme replacement therapy consisting of recombinant human glucuronidase beta...
BioCentury | Dec 18, 2017
Company News

Novartis buying Ultragenyx’s Priority Review voucher

...with about 200 patients worldwide. Mepsevii is an enzyme replacement therapy consisting of recombinant human glucuronidase beta...
BioCentury | Dec 8, 2017
Product Development

Making of Mepsevii

...and preclinical proof of efficacy. Mepsevii, for example, is an ERT consisting of recombinant human glucuronidase beta...
...development of Vimizim. Mepsevii also had a well-established mechanism of action. MPS VII patients lack glucuronidase beta...
...researchers in the Journal of Clinical Investigation in 1997 and 1998. The work showed recombinant glucuronidase beta...
BioCentury | Nov 17, 2017
Clinical News

FDA approves Ultragenyx's Mepsevii for MPS VII

...Review voucher with the approval. Mepsevii is an enzyme replacement therapy consisting of recombinant human glucuronidase beta...
BioCentury | Nov 15, 2017
Company News

FDA approves Ultragenyx's Mepsevii for MPS VII

...Review voucher with the approval. Mepsevii is an enzyme replacement therapy consisting of recombinant human glucuronidase beta...
BioCentury | Oct 6, 2017
Finance

Coasting on catalysts

...milestones for Ultragenyx Pharmaceutical Inc. Its vestronidase alpha ( rhGUS ; UX003), a recombinant human glucuronidase beta (GUSB)...
Items per page:
1 - 10 of 42